China's Innovent jumps as products included in National Reimbursement Drug List

China Renaissance Holdings

19/01/2023 04:55

** Shares of Chinese oncology treatment developer Innovent
Biologics Inc  1801.HK  jump as much as 6.4% to HK$43.30, on
track for the biggest daily pct rise since Jan. 9 if gains hold
    ** Stock hit the highest since Jan. 16 in the second session
of gain; sixth biggest percentage gainer in the Hang Seng
Composite Index  .HSCI  
    ** Jiangsu-based Innovent says five of its products -
TYVYT®, olverematinib, BYVASDA®, HALPRYZA® and SULINNO® - have
been included in the updated China's National Reimbursement Drug
List 2022 Version  urn:newsml:reuters.com:*:nFWN3431O1
    ** Co. has strategic collaborations with international
partners, including Eli Lilly and Company  LLY.N , Sanofi
 SASY.PA , Adimab, Incyte  INCY.O , MD Anderson Cancer Center 
    ** The Hang Seng Commerce & Industry Index  .HSNC  slips
0.2% while the healthcare index  .HSCIH  gains 0.9%
    ** The Hang Seng Composite Index  .HSCI  climbs 0.01% while
the Hang Seng Index  .HSI  slips 0.03%
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))